Alzheimer’s Disease International Webinar – “Let’s Talk About Dementia Research” – Tomorrow – 10th May 2019

On 10 May 2019, ADI will run the third in their global webinar series: Let’s Talk about Dementia Research.

This webinar will address an important topical question:

How do we maintain hope when trials end?

The discussion will enable pharmaceutical companies to tell their side of the story – the hopes and frustrations of conducting dementia research and clinical trials.

It will allow the public to ask important questions in order to better understand why trials are discontinued and what can be expected in the future, and will explore the role of the media in how clinical trials are reported on, especially when they are discontinued. Importantly, it will consider next steps – how can the public be more proactive?

They are excited to announce that the panellists sharing their opinions on dementia research and answering your questions will be:

Paola Barbarino, Chief Executive of Alzheimer’s Disease International

Professor Craig Ritchie, Chair, Psychiatry of Ageing, University of Edinburgh and Director of the Centre for Dementia Prevention

Dr. Eliezer Masliah, Director of the Division of Neuroscience, National Institute on Aging (NIA)

Dr. Philipp von Rosenstiel, Senior Medical Director, Clinical Development, Biogen

Dr. Martin Traber, Global Medical Lead, Alzheimer’s Disease, Roche

Howard Gordon, Global Advocate for Dementia and Rights

Final panel to be confirmed.

Join the debate, share your story, ask your question.

The series

In November 2018, ADI began our Let’s Talk About Dementia Research global webinar series on dementia research and clinical trials.

The idea of the series is to create a unique opportunity for the general public and Alzheimer and dementia associations to engage directly with health and social care professionals, as well as companies involved in dementia research and clinical trials.

As far as we know, no other webinar has provided such ‘public to professional’ access before.

Each webinar in the series aims to link and build upon the others. We hope to encourage lively debate and knowledge exchange; stimulating interest in research and trials to search for a disease-modifying treatment.

The series will conclude with a look ahead at overcoming some of these barriers and hopes for the future.